Lower rates of mutations in the pre-operative cohort to that expected in a Caucasian NSCLC population were observed, with only four EGFR (4%) mutations and nine KRAS (9%) mutations, all occurring in adenocarcinomas as expected. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.